Results 31 to 40 of about 312,772 (298)

Comparing the risk of anaphylaxis requiring epinephrine in oral immunotherapy and subcutaneous immunotherapy: A review of recent Canadian real-world literature

Journal of Allergy and Clinical Immunology: Global, 2023
Background: The safety of pediatric food oral immunotherapy (Ped-OIT) has been depicted by some as less favorable than subcutaneous immunotherapy (SCIT) owing to the increased number of serious adverse events requiring epinephrine. A review of real-world
Uliana Kovaltchouk, MD, FRCPC, Samira Jeimy, MD, PhD, FRCPC, Lianne Soller, PhD, Kara Robertson, MD, FRCPC, Elissa M. Abrams, MD, FRCPC, Scott B. Cameron, MD, PhD, FRCPC, Harold Kim, MD, FRCPC, Edmond S. Chan, MD, FRCPC   +7 more
doaj   +1 more source

Dose dependence of efficacy but not of safety in sublingual immunotherapy

Monaldi Archives for Chest Disease, 2016
Sublingual immunotherapy (SLIT) currently represents, as indicated by meta-analysis of its efficacy and safety, a valid option to the generally used traditional subcutaneous immunotherapy (SCIT) for treating respiratory allergy.
F. Frati, C. Incorvaia, F. Marcucci, L. Sensi, G. Di Cara, P. Puccinelli, S. Dal Bo   +6 more
doaj   +1 more source

Safety Profile and Issues of Subcutaneous Immunotherapy in the Treatment of Children with Allergic Rhinitis

Cells, 2022
This study aims to evaluate safety issues of house dust mite subcutaneous immunotherapy (SCIT) among allergic rhinitis (AR) children. A retrospective cohort study was done between 2015 and 2020 to investigate the side effects of SCIT among AR children ...
Anang Endaryanto, Ricardo Adrian Nugraha
doaj   +1 more source

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source

Transition between subcutaneous and sublingual allergen immunotherapy: Recommendations of the Brazilian Association of Allergy and Immunology (ASBAI)

Journal of Allergy and Clinical Immunology: Global
The use of allergen immunotherapy (AIT) in Brazil has specific regional conditions owing to the pattern of allergen sensitization, as well as to genetic, socioeconomic, and cultural characteristics.
Fernando Monteiro Aarestrup, MD, PhD, Ernesto Akio Taketomi, MD, PhD, Clóvis Eduardo Santos Galvão, MD, PhD, Gil Bardini Alves, MD, MSc, Geórgia Véras de Araújo Gueiros Lira, MD, PhD, Marcos Reis Gonçalves, MD, MSc, Mariana Graça Couto Miziara, MD, Sidney Souteban Maranhão Casado, MD, Veridiana Aun Rufino Pereira, MD, PhD, Dirceu Solé, MD, PhD, Ekaterini Simoes Goudouris, MD, PhD, Fabio Chigres Kuschnir, MD, PhD   +11 more
doaj   +1 more source

Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis

Clinical and Translational Allergy, 2020
Background Pollen and house dust mite (HDM) subcutaneous immunotherapy (SLIT) and pollen subcutaneous immunotherapy (SCIT) are effective therapies for children with allergic rhinoconjunctivitis (AR).
Thomas Proctor, Elodie Morrough, Otto Fenske, Sarah Allatt, Stephen M. Hughes, Vibha Sharma, Peter D. Arkwright   +6 more
doaj   +1 more source

Circulating C-X-C Motif Ligand 13 as a Biomarker for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With Chronic Allergic Rhinitis

Frontiers in Pediatrics, 2022
BackgroundC-X-C motif ligand 13 (CXCL13) and B cell-activating factor (BAFF) are proven to be involved in inflammatory diseases, but their role in allergic rhinitis (AR) remains unclear.
Shenghao Cheng, Shenghao Cheng, Shenghao Cheng, Sihui Wen, Sihui Wen, Sihui Wen, Shaobing Xie, Shaobing Xie, Shaobing Xie, Caixia Zhang, Caixia Zhang, Caixia Zhang, Hua Zhang, Hua Zhang, Hua Zhang, Kelei Gao, Kelei Gao, Kelei Gao, Ruohao Fan, Ruohao Fan, Ruohao Fan, Zhihai Xie, Zhihai Xie, Zhihai Xie, Weihong Jiang, Weihong Jiang, Weihong Jiang   +26 more
doaj   +1 more source

Effect of specific immunotherapy added to pharmachologic treatment and allergen avoidance in allergic asthma

, 2004
Although several studies support the efficacy of specific immunotherapy in allergic asthma, its benefit compared with that of standardized pharmacologic intervention remains unknown.
PIACENTINI, Giorgio, Maestrelli P., Zanolla L, on behalf of the Regione Veneto Study Group on the ‘‘Effect of immunotherapy in allergic asthma’’, Fabbri L, Pozzan M   +5 more
core   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Pollen-food allergy syndrome and lipid transfer protein syndrome: Clinical relevance

Indian Journal of Allergy Asthma and Immunology, 2021
The role of an allergist in recognizing the pollen-food allergy syndrome (PFAS) and lipid transfer protein syndrome (LTPS) is essential. LTPS differs from PFAS by having a different family of panallergens and clinical characteristics.
P C Kathuria, Manisha Rai
doaj   +1 more source